A medical breakthrough has been made by scientists after a new drug called lecanemab proved to work for the first time against the much dreaded Alzheimer’s disease for which there is no known treatment only an array of previously failed studies reports The Sun.
According to the news report, lecanemab acts by clearing out proteins which build up in the brain and cause the disease.
Japanese drug firm Eisai and Biogen, in the US, say their jab helps stave off nerve damage and buys sufferers extra time.
The new study tested 900 people who were given the drug over 18 months recorded brain and by the end and scored 27 per cent higher.
Alzheimer’s Research UK said: “This is an historic moment for dementia research.
“This is the first drug that’s been shown to not only remove the build-up of protein, but to have a significant impact on cognitive decline.
Dementia expert Prof Rob Howard, of University College London, added: “God knows, we’ve waited long enough for this.”
RESOURCE | ABOUT LECANEMAB
Lecanemab (development code BAN2401) is an experimental drug jointly developed by the companies Biogen and Eisai that is currently in clinical trials for the treatment of Alzheimer's disease. It was announced in late November 2022 that drug was a success in clinical trials and exceeded its goal in reaching primary endpoints. The company is on track to apply for FDA approval by March 2023.[Wiki]